UroGen Pharma Ltd URGN
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 4th percentile, 5-year average -4.9x
Below its usual level · 31st percentile, 5-year average -5.5x
Below its usual level · 39th percentile, 5-year average 6.4x
#3963 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -10.25 | – | -5.46 | 31% (cheaper than usual) | – |
| PE | -19.98 | 10.14 | -4.94 | 4% (cheaper than usual) | – |
| PS | 5.13 | 2.64 | 6.43 | 39% (cheaper than usual) | #3963 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on URGN.
Sign in to join the discussion.